Metformin repurposing in gout: enhancing febuxostat efficacy through anti-inflammatory and metabolic modulation: a randomized controlled double-blind study
Dalia N Abdel-Sadek, Tarek M Abd-Elazez, Sahar M El-Haggar · 2026
Read Metformin repurposing in gout: enhancing febuxostat efficacy through anti-inflammatory and metabolic modulation: a randomized controlled double-blind study by Dalia N Abdel-Sadek, Tarek M Abd-Elazez, Sahar M El-Haggar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13391746.txt.
Description
Dalia N Abdel-Sadek's team tested adding metformin to febuxostat for gout in a randomised, double-blind trial of sixty patients, thirty per arm. Gout brings recurrent painful flares and high uric acid, and metformin's calming and metabolism-linked effects might add benefit beyond urate lowering.
Both groups better on all markers, but the metformin group showed clearly larger drops in pain scores, TNF-alpha, interleukin-1 beta, and uric acid, plus significant falls in free fatty acids and triglycerides. The combination thus looks promising for gout, pending larger trials on flares and long-term safety.
Catalog record
| CREATOR | Dalia N Abdel-Sadek, Tarek M Abd-Elazez, Sahar M El-Haggar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |